title: [The treatment of aplastic anemia with antilymphocyte globulin].
abstract: Made in Russia antilymphocytic globulin (ALG) was given to 43 patients with aplastic anemia (AA). 56% of the patients responded, 30% reached a complete or partial remission. 5-year actuarial survival of ALG-treated patients was 52% (44 and 60% for severe and non-severe forms). The data on ALG efficacy suggest its benefits in first-line therapy of both severe and non-severe AA as well as in management of patients resistant to other methods of immunosuppressive treatment.
authors.forename: E A
authors.initials: EA
authors.lastname: Mikhaĭlova
authors.forename: V G
authors.initials: VG
authors.lastname: Savchenko
authors.forename: E R
authors.initials: ER
authors.lastname: Maslova
authors.forename: E N
authors.initials: EN
authors.lastname: Ustinova
mesh_terms: D000206:Actuarial Analysis; D000293:Adolescent; D000328:Adult; D000741:Anemia, Aplastic / Q000150:complications / Q000401:mortality / Q000628:therapy*; D000961:Antilymphocyte Serum / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004341:Drug Evaluation; D005260:Female; D006470:Hemorrhage / Q000209:etiology / Q000628:therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D008297:Male; D012074:Remission Induction; D013577:Syndrome; D013997:Time Factors
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents